演題抄録

International Session(Poster)

開催概要
開催回
第51回・2013年・京都
 

Cost analysis of S1 and XELOX as adjuvant therapy for gastric cancer

演題番号 : ISP-10

[筆頭演者]
Wen Feng:1 
[共同演者]
He Jianping:1、Yin Xude:2、Zhang Pengfei:1、Du Zedong:3、He Xiaofeng:4、Zhou Yi:1、Tang Ruilei:1、Li Meng:1、Li Qiu:1

1:Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, China、2:The Department of Medical Oncology, Sichuan Cancer Hospital, China、3:The Department of Oncology, 363 Hospital, China、4:The Department of Medical Oncology, First People's Hospital of Longquanyi District, China

 

Background: Both S1 and XELOX (capecitabine + oxaliplatin) have been recommended as the adjuvant treatment for gastric cancer (GC) according to National Comprehensive Cancer Network (NCCN) guidelines. This study compared the two regimens in terms of monetary costs, assuming equal efficacy of both regimens. Methods: Chemotherapy cost data of 188 patients were collected from the medical records, 91 for S1 group and 97 for XELOX. Costs were classified as direct costs (chemotherapy, hospitalization, venous access and tests), adverse events (AE)-related treatments costs and societal (travel and time) costs. Results: The total direct cost of S1 and XELOX per cycle per patient were $1,938±236 and $2,317±315 respectively. S1 cost $ 27 and $9 less than XELOX on total AE-related costs and societal costs, respectively. Total cost of S1 and XELOX were $1,994±322 VS $ 2,410 ± 391 per cycle per patient, respectively. The total cost of S1 was 17.3% less than that of XELOX for the average patient. All the differences were statistically significant.Conclusion: S1, compared with XELOX, could be a more affordable option as adjuvant treatment for GC when all healthcare resources were taken into account in China.

前へ戻る